Holen Sie sich die Stockscreener-App
37.13
2.57%
0.9639
Schlusskurs vom Vortag:
$36.17
Offen:
$36.23
24-Stunden-Volumen:
1.36M
Relative Volume:
0.54
Marktkapitalisierung:
$10.98B
Einnahmen:
$2.08B
Nettoeinkommen (Verlust:
$466.92M
KGV:
23.80
EPS:
1.56
Netto-Cashflow:
$404.94M
1W Leistung:
-6.88%
1M Leistung:
+5.07%
6M Leistung:
+3.49%
1J Leistung:
+73.61%
1-Tages-Spanne:
$36.23
$37.30
1-Wochen-Bereich:
$34.90
$39.38
52-Wochen-Spanne:
$20.14
$40.26
Exelixis Inc Stock (EXEL) Company Profile
Firmenname
Exelixis Inc
Sektor
Branche
Telefon
(650) 837-7000
Adresse
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Vergleichen Sie EXEL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
37.15 | 10.98B | 2.08B | 466.92M | 404.94M | 1.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.14 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.51 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
559.06 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
267.22 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
232.21 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2024-09-19 | Eingeleitet | UBS | Neutral |
| 2024-04-11 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Eingeleitet | BTIG Research | Buy |
| 2023-12-15 | Eingeleitet | Citigroup | Buy |
| 2023-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-22 | Bestätigt | Oppenheimer | Outperform |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-09 | Eingeleitet | Wells Fargo | Overweight |
| 2023-01-26 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-11-03 | Fortgesetzt | Jefferies | Buy |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Sell |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-18 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Eingeleitet | Goldman | Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Underweight |
| 2018-05-11 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-16 | Bestätigt | SunTrust | Buy |
| 2017-09-22 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-09-12 | Bestätigt | Needham | Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Buy |
| 2017-03-31 | Eingeleitet | Needham | Buy |
| 2017-03-16 | Eingeleitet | Oppenheimer | Perform |
| 2017-02-28 | Herabstufung | Stifel | Buy → Hold |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2016-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Bestätigt | Stifel | Buy |
Alle ansehen
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
(EXEL) Trading Advice - news.stocktradersdaily.com
Is Exelixis, Inc. (EXEL) One of the Best Stocks to Buy According to Jim Simons’ Renaissance Technologies? - Insider Monkey
Investor Network: Exelixis, Inc. to Host Earnings Call - ACCESS Newswire
Analyst Favorites With Strong Buyback Activity: Exelixis Ranks As a Top Pick - Nasdaq
Ahead of Exelixis (EXEL) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics - Yahoo Finance
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May - Business Wire
Exelixis (EXEL) Stock Price, News & Analysis - MarketBeat
Exelixis, Inc. (EXEL): Among the Large-Cap Stocks Insiders and Short Sellers Are Dumping Like Crazy - Insider Monkey
BlackRock, Inc. Reduces Stake in Exelixis Inc. - GuruFocus
Here's Why Exelixis (EXEL) is a Strong Momentum Stock - Yahoo Finance
(EXEL) Proactive Strategies - news.stocktradersdaily.com
Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025 - BioSpace
Exelixis to Release First Quarter 2025 Financial Results on Tues - GuruFocus
Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025 | EXEL Stock News - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum? - MSN
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge - ADVFN
Exelixis Reaches Analyst Target Price - Nasdaq
Here's Why Exelixis (EXEL) is a Strong Value Stock - Yahoo Finance
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release - Yahoo Finance
Expert Outlook: Exelixis Through The Eyes Of 19 Analysts - Benzinga
Citizens JMP reiterates Exelixis stock with $41 target By Investing.com - Investing.com Canada
Citizens JMP reiterates Exelixis stock with $41 target - Investing.com
Exelixis, Inc. (NASDAQ:EXEL) Position Boosted by Summit Investment Advisors Inc. - MarketBeat
Market Participants Recognise Exelixis, Inc.'s (NASDAQ:EXEL) Earnings - simplywall.st
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term - Yahoo Finance
(EXEL) Investment Analysis - news.stocktradersdaily.com
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Prostate Cancer Pipeline Analysis and Clinical Trials - openPR.com
Private Sector Steps Up in Cancer Research as Federal Support Wavers - Baystreet.ca
Non-Small-Cell Lung cancer (NSCLC) Pipeline Analysis - openPR.com
Guggenheim maintains Exelixis stock with $42 target By Investing.com - Investing.com India
Guggenheim maintains Exelixis stock with $42 target - Investing.com
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance
Exelixis (EXEL) Gets a Buy from RBC Capital - The Globe and Mail
The Smartest Biotech Stocks to Buy With $50 - The Motley Fool
FY2026 EPS Estimates for Exelixis Lifted by Leerink Partnrs - MarketBeat
Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now? - MSN
Trexquant Investment LP Has $19.82 Million Stake in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Blair William & Co. IL Sells 300,760 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Finanzdaten der Exelixis Inc-Aktie (EXEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):